Table 3.
Summary of immunogenicity and safety results of all included JE vaccines
| Vaccine type | Immunogenicity | Safety | |||
|---|---|---|---|---|---|
| Number of studies | GMT | Seroconversion rate | Number of studies | AEs | |
| JE-CV | 12 | 128–2634 | 84–100% | 13 | Diarrhea; fatigue; feeling hot and cold; headache; injection site erythema; injection site pain; malaise; myalgia; nasal congestion; nausea; pyalgia |
| IXIARO | 10 | 182–2496 | 83–100% | 10 | Fever; hardening; headache; itching; myalgia; pain; rash; redness; swelling; tenderness; vomiting or diarrhea |
| Live attenuated SA14-14-2 virus vaccine | 8 | 115–517 | 83–100% | 8 | Anaphylaxis; angioedema; arthus reaction; elevated temperature; generalized rash; henoch-schonlein purpura; idiopathic thrombocytopenic purpura; irritability; loss of appetite; measles-like or scarlet fever rash; skin rash; urticarial; vomiting |
| Inactivated, Vero cell-derived JE vaccines | 6 | 70–622 | 87–100% | 1 | Tenderness; redness; ecchymosis; fever; vomiting; loss of appetite |
| MBJEV | 5 | 15–306 | 85–93% | 1 | Low-grade fever; injection site pain, rash or swelling |
| Inactivated JE vaccine (PHK) | 1 | 1:328 | 94.90% | 2 | Erythema; fever |
AEs: Adverse events; GMT: Geometric mean titer.